Aznab Mozaffar, Hematti Maryam
Department of Internal Medicine, Talaghani Hospital, Kermanshah University of Medical Sciences, Kermanshah 6714415333, Iran.
Department of Obstetrics, Shahid Beheshti BLND, Kermanshah 6714415333, Iran.
J Cancer Res Ther. 2017 Apr-Jun;13(2):291-296. doi: 10.4103/0973-1482.199447.
The aim of this study was to evaluate the effect of adding etoposide and ifosfamide chemotherapy drugs to treatment regimen of patients affected with osteosarcoma and to determine the clinical process and response to treatment during a follow-up period of 11 years.
Forty patients with osteosarcoma participated in this study from July 2005 to 2016. Treatments were started based on the following schema and after initial examinations including biochemical profile, checking for lung metastasis by simple radiography, chest computed tomography scan, and bones scan. The initial chemotherapy which consisted of four cycles of cisplatin and adriamycin alternative with ifosfamide and etoposide was provided. Afterward, resection of the primary tumor and also the metastatic lesions was performed in patients with lung metastasis in case they had radiological evidence of response to the treatment.
The mean of follow-up duration in this study was 50 months. Thirty-four patients did not have metastasis and six were metastatic. Of 34 patients, 18 had relapse and 16 patients never had relapse. Five patients experienced only local relapse, nine had only systemic relapse, and two patients had simultaneous systemic and local relapses. Thirteen patients had died. The mean of overall survival in patients was 81 months. The mean of survival in patients with and without primary metastasis was 30 and 90 months, respectively.
Favorable response to the treatment was obtained with an appropriate multiple disciplinary works in the osteosarcomas of extremities, and there were no considerable side effects and sequels in the long-term follow-up of these treatments.
本研究旨在评估在骨肉瘤患者的治疗方案中添加依托泊苷和异环磷酰胺化疗药物的效果,并确定在11年随访期内的临床过程及对治疗的反应。
2005年7月至2016年,40例骨肉瘤患者参与了本研究。治疗基于以下方案开始,且在包括生化指标、通过简单X线摄影、胸部计算机断层扫描和骨扫描检查肺转移等初始检查之后进行。提供了由四个周期的顺铂和阿霉素交替联合异环磷酰胺和依托泊苷组成的初始化疗。之后,对于有肺转移且有影像学治疗反应证据的患者,进行原发性肿瘤及转移病灶的切除。
本研究的平均随访时间为50个月。34例患者无转移,6例有转移。在34例无转移的患者中,18例复发,16例从未复发。5例仅发生局部复发,9例仅发生全身复发,2例同时发生全身和局部复发。13例患者死亡。患者的总生存期平均为81个月。有原发转移和无原发转移患者的生存期平均分别为30个月和90个月。
通过对四肢骨肉瘤进行适当的多学科治疗,获得了良好的治疗反应,且这些治疗的长期随访中没有明显的副作用和后遗症。